Dr. Bowden is the Chief Medical Officer at Remix Therapeutics, a private biotechnology company, developing small molecule therapies designed to reprogram RNA processing and treat disease. From 2014–2021 he was the Chief Medical Officer at Agios Pharmaceuticals where he led clinical development activities that resulted in the approvals for IDH inhibitors in multiple indications including acute myeloid leukemia, cholangiocarcinoma and pivotal development of Pyruvate Kinase Activators.
Previously, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech. During his eight years there, Dr. Bowden was responsible for the successful development of a number of novel targeted oncology medicines, including Zelboraf™ for patients with BRAF V600E positive melanoma, and Tarceva™ for patients with EGFR activating mutation positive, non-small cell lung cancer.
From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, and Africa) regions for Bristol Myers Squibb. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Sciences Center, where he participated in numerous industry and cooperative group trials. He serves on the board of directors at Akamis Bio and is on the Clinical Advisory Board of C4 Therapeutics. Dr. Bowden is board certified in internal medicine and medical oncology.